Helical Tomotherapy in Multiple Myeloma
To explore the safety and efficacy of systemic radiotherapy (TBI) combined with melphalan (Mel) for pretreatment of autologous hematopoietic stem cells in multiple myeloma.
Multiple Myeloma
RADIATION: Total Marrow irradiation，TMI|PROCEDURE: Autologous hematopoietic stem cell transplantation
Complete response rate and above 100 days after transplantation (≥ CR rate), Complete response rate and above 100 days after transplantation (≥ CR rate), through study completion, an average of 1 year
1-year Progression-free Survival rate, 1-year Progression-free Survival rate, 1 year
1-year Overall Survival rate, 1-year Overall Survival rate, 1 year|Platelet implantation time, Platelet implantation time, 3 months|Neutrophil implantation time, Neutrophil implantation time, 3 months
This study is a single-center, prospective clinical study targeting myeloma patients requiring transplantation, and investigating the efficacy and safety of TBI combined with Mel regimen for transplant pretreatment. Subjects who meet the enrollment criteria were screened to enter the study and receive the corresponding regimen treatment.